These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 28855072)

  • 1. Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical Research.
    Necchi A; Raggi D; Volpi CC; Giannatempo P; Colecchia M; Gloghini A
    Eur Urol Focus; 2019 Jul; 5(4):689-692. PubMed ID: 28855072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
    Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
    Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
    Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
    Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identifying fibroblast growth factor receptor genetic alterations using RNA-based assays in patients with metastatic or locally advanced, surgically unresectable, urothelial carcinoma who may benefit from erdafitinib treatment.
    Wang S; Burgess M; Major C; English A; Sweeney M; Hartmann A
    J Pathol Clin Res; 2020 Jul; 6(3):207-214. PubMed ID: 32304281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
    Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
    Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
    Souza VC; Monteiro FSM; Maluf FC; Werutsky G; Fabrício VC; Gidekel R; Gandur-Quiroga MN; Freitas MRP; Luz M; Campos-Gomez S; Junior JAR; Bastos DA; Sade JP; da Trindade KM; Mota ACA; Fernandes RC; Ruíz AOB; Pereira E Silva BD; de Oliveira FNG; Cutuli HJ; Nogueira L; Aceituno LFG; Fernandez M; Inman E; Caitano M; Herchenhorn D; Ardila-Salcedo J; Pacheco P; de Jesus RG; Gössling G; Soares A; Fay AP
    Clin Genitourin Cancer; 2024 Oct; 22(5):102174. PubMed ID: 39181783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
    Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
    Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting FGFR in bladder cancer: ready for clinical practice?
    De Keukeleire S; De Maeseneer D; Jacobs C; Rottey S
    Acta Clin Belg; 2020 Feb; 75(1):49-56. PubMed ID: 31671027
    [No Abstract]   [Full Text] [Related]  

  • 9. Localisation and differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal and atherosclerotic human arteries.
    Hughes SE
    Cardiovasc Res; 1996 Sep; 32(3):557-69. PubMed ID: 8881516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of FGFR alteration on prognosis in 1963 urothelial carcinoma patients with immune checkpoint inhibitors: Implying combination of FGFR inhibitor and immunotherapy for FGFR-altered urothelial carcinoma.
    Song Y; Jiang S; Peng Y; Qin C; Du Y; Xu T
    Pharmacol Res; 2024 Jul; 205():107230. PubMed ID: 38788820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
    Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions.
    Madison RW; Gupta SV; Elamin YY; Lin DI; Pal SK; Necchi A; Miller VA; Ross JS; Chung JH; Alexander BM; Schrock AB; Heymach JV; Reddy P; Ali SM
    BJU Int; 2020 May; 125(5):739-746. PubMed ID: 31985116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of basic fibroblast growth factor and fibroblast growth factor receptor in advanced gastric carcinoma.
    Ueki T; Koji T; Tamiya S; Nakane PK; Tsuneyoshi M
    J Pathol; 1995 Dec; 177(4):353-61. PubMed ID: 8568589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of next generation sequencing in advanced urothelial carcinoma.
    Tripathi A; Grivas P
    Eur Urol Focus; 2020 Jan; 6(1):41-44. PubMed ID: 31708470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.
    Qin A; Johnson A; Ross JS; Miller VA; Ali SM; Schrock AB; Gadgeel SM
    J Thorac Oncol; 2019 Jan; 14(1):54-62. PubMed ID: 30267839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Molecular tumor board-urothelial cancer].
    Hupe MC; Gakis G; Seiler R
    Urologe A; 2019 Jul; 58(7):760-767. PubMed ID: 31172245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequent FGFR3 mutations in urothelial papilloma.
    van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
    J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma.
    Kardoust Parizi M; Margulis V; Lotan Y; Mori K; Shariat SF
    Urol Oncol; 2021 Jul; 39(7):409-421. PubMed ID: 33642228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Profiling and Molecular Characterisation of Metastatic Urothelial Carcinoma.
    Pezzicoli G; Ciciriello F; Musci V; Minei S; Biasi A; Ragno A; Cafforio P; Rizzo M
    Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.